Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 178

1.

The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis.

Maayah ZH, Takahara S, Ferdaoussi M, Dyck JRB.

Inflamm Res. 2020 Apr 1. doi: 10.1007/s00011-020-01341-1. [Epub ahead of print] Review.

PMID:
32239248
2.

The molecular mechanisms that underpin the biological benefit of full spectrum cannabis extract in the treatment of neuropathic pain and inflammation.

Maayah ZH, Takahara S, Ferdaoussi M, Dyck JRB.

Biochim Biophys Acta Mol Basis Dis. 2020 Mar 19:165771. doi: 10.1016/j.bbadis.2020.165771. [Epub ahead of print] Review.

PMID:
32201189
3.

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.

Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, Levasseur JL, Jahng JWS, Vos D, Parajuli N, El-Kadi AOS, Braam B, Young ME, Verma S, Light PE, Sweeney G, Seubert JM, Dyck JRB.

Circ Heart Fail. 2020 Jan;13(1):e006277. doi: 10.1161/CIRCHEARTFAILURE.119.006277. Epub 2020 Jan 20.

PMID:
31957470
4.

Human Pharmacokinetic Parameters of Orally Administered Ī”9-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences.

Lunn S, Diaz P, O'Hearn S, Cahill SP, Blake A, Narine K, Dyck JRB.

Cannabis Cannabinoid Res. 2019 Dec 6;4(4):255-264. doi: 10.1089/can.2019.0037. eCollection 2019.

PMID:
31872060
5.

Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results.

Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, Guzzardi DG, Svystonyuk DA, Pattar SS, Park DSJ, Turnbull JD, Duff HJ, Tibbles LA, Cunnington RH, Dyck JRB, Fedak PWM.

Can J Cardiol. 2020 Apr;36(4):543-553. doi: 10.1016/j.cjca.2019.08.033. Epub 2019 Aug 29.

PMID:
31837891
6.

Quantification of lung water in heart failure using cardiovascular magnetic resonanceĀ imaging.

Thompson RB, Chow K, Pagano JJ, Sekowski V, Michelakis ED, Tymchak W, Haykowsky MJ, Ezekowitz JA, Oudit GY, Dyck JRB, Kaul P, Savu A, Paterson DI.

J Cardiovasc Magn Reson. 2019 Sep 12;21(1):58. doi: 10.1186/s12968-019-0567-y.

7.

Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction.

Wang W, Zhang L, Battiprolu PK, Fukushima A, Nguyen K, Milner K, Gupta A, Altamimi T, Byrne N, Mori J, Alrob OA, Wagg C, Fillmore N, Wang SH, Liu DM, Fu A, Lu JY, Chaves M, Motani A, Ussher JR, Reagan JD, Dyck JRB, Lopaschuk GD.

JACC Basic Transl Sci. 2019 Jun 24;4(3):385-400. doi: 10.1016/j.jacbts.2019.02.003. eCollection 2019 Jun.

8.

Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure.

Uddin GM, Zhang L, Shah S, Fukushima A, Wagg CS, Gopal K, Al Batran R, Pherwani S, Ho KL, Boisvenue J, Karwi QG, Altamimi T, Wishart DS, Dyck JRB, Ussher JR, Oudit GY, Lopaschuk GD.

Cardiovasc Diabetol. 2019 Jul 5;18(1):86. doi: 10.1186/s12933-019-0892-3.

9.

External Validation of the H2F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction.

Sepehrvand N, Alemayehu W, Dyck GJB, Dyck JRB, Anderson T, Howlett J, Paterson I, McAlister FA, Ezekowitz JA.

Circulation. 2019 May 14;139(20):2377-2379. doi: 10.1161/CIRCULATIONAHA.118.038594. No abstract available.

PMID:
31082301
10.

The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review.

Dyck GJB, Raj P, Zieroth S, Dyck JRB, Ezekowitz JA.

Int J Mol Sci. 2019 Feb 19;20(4). pii: E904. doi: 10.3390/ijms20040904. Review.

11.

Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency.

Ho KL, Zhang L, Wagg C, Al Batran R, Gopal K, Levasseur J, Leone T, Dyck JRB, Ussher JR, Muoio DM, Kelly DP, Lopaschuk GD.

Cardiovasc Res. 2019 Sep 1;115(11):1606-1616. doi: 10.1093/cvr/cvz045.

PMID:
30778524
12.

Resveratrol improves cardiac function and exercise performance in MI-induced heart failure through the inhibition of cardiotoxic HETE metabolites.

Matsumura N, Takahara S, Maayah ZH, Parajuli N, Byrne NJ, Shoieb SM, Soltys CM, Beker DL, Masson G, El-Kadi AOS, Dyck JRB.

J Mol Cell Cardiol. 2018 Dec;125:162-173. doi: 10.1016/j.yjmcc.2018.10.023. Epub 2018 Oct 28.

PMID:
30381233
13.

Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction.

Fillmore N, Levasseur JL, Fukushima A, Wagg CS, Wang W, Dyck JRB, Lopaschuk GD.

Mol Med. 2018 Mar 15;24(1):3. doi: 10.1186/s10020-018-0005-x.

14.

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.

Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, Fedak PWM, Verma S, Dyck JRB.

JACC Basic Transl Sci. 2017 Aug 4;2(4):347-354. doi: 10.1016/j.jacbts.2017.07.003. eCollection 2017 Aug. Review.

15.

Atglistatin ameliorates functional decline in heart failure via adipocyte-specific inhibition of adipose triglyceride lipase.

Parajuli N, Takahara S, Matsumura N, Kim TT, Ferdaoussi M, Migglautsch AK, Zechner R, Breinbauer R, Kershaw EE, Dyck JRB.

Am J Physiol Heart Circ Physiol. 2018 Oct 1;315(4):H879-H884. doi: 10.1152/ajpheart.00308.2018. Epub 2018 Jun 22.

16.

Insulin decreases expression of the proinflammatory receptor proteinase-activated receptor-2 on human airway epithelial cells.

Gandhi VD, Shrestha Palikhe N, Hamza SM, Dyck JRB, Buteau J, Vliagoftis H.

J Allergy Clin Immunol. 2018 Sep;142(3):1003-1006.e8. doi: 10.1016/j.jaci.2018.04.040. Epub 2018 Jun 8. No abstract available.

PMID:
29890235
17.

Fecal transplant from resveratrol-fed donors improves glycaemia and cardiovascular features of the metabolic syndrome in mice.

Kim TT, Parajuli N, Sung MM, Bairwa SC, Levasseur J, Soltys CM, Wishart DS, Madsen K, Schertzer JD, Dyck JRB.

Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E511-E519. doi: 10.1152/ajpendo.00471.2017. Epub 2018 Jun 5.

18.

Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes.

Matsumura N, Zordoky BN, Robertson IM, Hamza SM, Parajuli N, Soltys CM, Beker DL, Grant MK, Razzoli M, Bartolomucci A, Dyck JRB.

Cardiovasc Res. 2018 Aug 1;114(10):1350-1359. doi: 10.1093/cvr/cvy064.

19.

2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy.

Maayah ZH, Levasseur J, Siva Piragasam R, Abdelhamid G, Dyck JRB, Fahlman RP, Siraki AG, El-Kadi AOS.

Sci Rep. 2018 Feb 9;8(1):2780. doi: 10.1038/s41598-018-20613-9.

20.

Cardiac adaptations to obesity, diabetes and insulin resistance.

Glatz JFC, Dyck JRB, Des Rosiers C.

Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt B):1905-1907. doi: 10.1016/j.bbadis.2018.01.024. Epub 2018 Jan 31. No abstract available.

Supplemental Content

Loading ...
Support Center